854107-55-4 Usage
Description
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one is a complex organic compound with a unique molecular structure. It is characterized by the presence of a thiazolidin-4-one ring, a benzylidene group, and various functional groups such as chloro, hydroxy, and propylamine. (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one exhibits a range of biological activities and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one is used as a potential therapeutic agent for the treatment of various diseases. Its unique molecular structure allows it to modulate biological targets and pathways, making it a promising candidate for drug development.
Used in Anti-inflammatory Applications:
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one is used as an anti-inflammatory agent, particularly for the treatment of lymphocyte-mediated tissue inflammation. It functions as a sphingosine-1-phosphate receptor agonist, similar to Ponesimod, and helps protect against inflammation by modulating the immune response.
Used in Drug Delivery Systems:
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one can be employed in drug delivery systems to improve the bioavailability and therapeutic efficacy of various drugs. Its unique chemical properties allow it to be incorporated into different drug delivery platforms, such as nanoparticles, liposomes, and hydrogels, to enhance the delivery of therapeutic agents to target tissues.
Biological Activity
ec50: 5.7 nmponesimod is a sphingosine-1-phosphate receptor 1 (s1p1) modulator.lymphocyte exit from lymph nodes and its recirculation into blood is reported to be controlled by s1p. the cellular receptor mediating lymphocyte exit is one of five s1p receptors, s1p1. thus, the nonselective agonists for s1p1 lead to blood lymphocyte count reduction.
in vitro
previous study found that ponesimod could activate s1p1-mediated signal transduction with high potency. moreover, relative to the potency for s1p, the potency of ponesimod at human recombinant receptors was 4.4-fold higher for s1p1 and 150-fold lower for human s1p3. thus, ponesimod was 650-fold more selective for human s1p1 over s1p3 than the endogeneous ligand [1].
in vivo
animal study showed that the oral administration of ponesimod to rats resulted in a dose-dependent decrease of blood lymphocyte count, and the blood lymphocyte count returned to baseline within 48 h after discontinuation of ponesimod treatment. in addition, ponesimod prevented inflammatory cell accumulation, edema formation, as well as cytokine release in the skin of mice with delayed-type hypersensitivity. furthermore, in rats with adjuvant-induced arthritis, ponesimod could also prevent the increase in paw volume and joint inflammation [2].
references
[1] piali l, froidevaux s, hess p, nayler o, bolli mh, schlosser e, kohl c, steiner b, clozel m. the selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. j pharmacol exp ther. 2011 may;337(2):547-56. [2] d'ambrosio d, freedman ms, prinz j. ponesimod, a selective s1p1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. ther adv chronic dis. 2016 jan;7(1):18-33.
Check Digit Verification of cas no
The CAS Registry Mumber 854107-55-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,4,1,0 and 7 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 854107-55:
(8*8)+(7*5)+(6*4)+(5*1)+(4*0)+(3*7)+(2*5)+(1*5)=164
164 % 10 = 4
So 854107-55-4 is a valid CAS Registry Number.
854107-55-4Relevant articles and documents
PROCESS FOR THE PREPARATION OF|(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-|(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS
-
, (2014/03/22)
The present invention relates to a new process for the preparation of (2Z,5Z)-5-(3-chloro-4- ((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and to the new intermediate (R)-3-chloro-4-(2,3-dihydroxypropoxy)-benzaldehyde used in this process. (2Z,5Z)-5-(3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3- (o-tolyl)thiazolidin-4-one is described in WO 2005/054215 to act as an immunosuppressive agent. The present invention further also relates to a new process for the preparation of (R)-3-chloro-4-(2,3-dihydroxypropoxy)-benzaldehyde.
5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS
-
Page/Page column 28; 70, (2008/06/13)
The invention relates to pharmaceutical compositions containing at least one 5- (benz- (Z) -ylidene-thiazolidin-4-one derivative (I), to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thi
